Cerevance Media Center

Current News

October 5, 2017

Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., to Advise Cerevance

Cerevance, a drug discovery and development company, today announced that Robert Malenka, M.D., Ph.D., has joined the company as a senior-level scientific advisor.  Dr. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences at Stanford University.

READ FULL

May 3, 2017

Dementia Discovery Fund to Invest $5M in Cerevance to Seek New Treatments for Dementia

The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investment in the initial financing round of start-up drug discovery company, Cerevance.

READ FULL

December 2, 2016

Cerevance Launched With New Technology, Drug Portfolio and $36M in Cash to Tackle Brain Diseases

  • Takeda and Lightstone Ventures Participate in Series A Financing
  • Former Takeda Cambridge UK employees, CNS programs moved to create turn-key discovery capabilities
READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

September 23, 2024

Cerevance to Participate in a Panel Discussion at Fierce Biotech Summit 2024

Date:
Tuesday, October 1, 2024
Time:
2:15 – 3:00 PM EDT
Location:
Boston, MA
Media:
Panel Discussion
Read full

May 20, 2024

Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention

Date:
Tuesday, June 4, 2024
Time:
11 am – 12 pm, PT
Location:
San Diego, CA
Media:
Panel Discussion
Read full

May 9, 2024

Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders

Date:
Monday, May 20, 2024
Time:
9:35 – 10:20am
Location:
Lisbon, Portugal
Media:
Oral Presentation
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

June 27, 2024

CryoEM Structure of the human THIK-1 K2P K+ Channel Reveals a Lower ‘Y-gate’ Regulated by Lipids and Anaesthetics

Rödström, K. E.J., Eymsh, B., Proks, P., Hayre, M. S., Madry, C., Rowland, A., Newstead, S., Baukrowitz, T., Schewe, M., Tucker, S. J.

Viewview

January 26, 2023

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor

Mu, C., Li, X., Yang, Y., Zhou, Y., Wang, C., Doyle, K.J., Ye, N., Mistry, A., Burli, R.

Viewview

December 1, 2020

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate

Sun, H., Monenschein, H., Schiffer, H.H., Reichard, H.A., Kikuchi, S., Hopkins, M., Macklin, T.K., Hitchcock, S., Adams, M., Green, J., Brown, J., Murphy, S.T., Kaushal, N., Collia, D.R., Moore, S., Ray, W.J., English, N.M., Carlton, M.B, Brice, N.L.

Viewview

February 26, 2024

Differential Contribution of THIK‑1 K+ Channels and P2X7 Receptors to ATP‑Mediated Neuroinflammation by Human Microglia

Rifat, A., Ossola, B., Bürli, R. W. , Dawson, L. A., Brice, N. L., Rowland, A., Lizio, M., Xu, X., Page, K., Fidzinski, P., Onken, J., Holtkamp, M., Heppner, F. L., Geiger, J. R. P., Madry, C.

Viewview

March 21, 2022

The Two Pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation

Drinkall, S., Lawrence, C.B., Ossola, B., Russell, S., Bender, C., Brice, N.L., Dawson, L.A., Harte, M., Brough D.

Viewview

November 21, 2022

Pharmacological Targeting of Glutamatergic Neurons within the Brainstem for Weight Reduction

Schneeberger, M., Brice, N.L., Pellegrino, K., Parolar, L., Shaked, J.T., Page, K., Marchildon, F., Barrows, D., Carroll, T.S., Tolpiko, T., Mulligan, V., Barker, D., Glen, A., Newman, R., Ortuño, M.J., Renier, N., Nectow, A.R., Cohen, P., Carlton, M., Heintz, N., Friedman, J.M.

Viewview